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Though many individual transcription factors are
known to regulatehematopoieticdifferentiation,major
aspects of the global architecture of hematopoiesis
remain unknown. Here, we profiled gene expression
in 38 distinct purified populations of human hemato-
poietic cells and used probabilistic models of gene
expression and analysis of cis-elements in gene
promoters todecipher thegeneral organizationof their
regulatory circuitry. We identified modules of highly
coexpressed genes, some of which are restricted to
a single lineage but most of which are expressed at
variable levels across multiple lineages. We found
densely interconnected cis-regulatory circuits and
a large number of transcription factors that are differ-
entiallyexpressedacrosshematopoieticstates.These
findings suggest a more complex regulatory system
for hematopoiesis than previously assumed.INTRODUCTION
Hematopoiesis is an ideal model for the study of multilineage
differentiation in humans. More than 2 3 1011 hematopoietic
cells from at least 11 lineages are produced daily in humans
from a small pool of self-renewing adult stem cells (Quesenberry
and Colvin, 2005). Production of each cell type is highly regu-
lated and responsive to environmental stimuli. Mutations or296 Cell 144, 296–309, January 21, 2011 ª2011 Elsevier Inc.aberrant expression of regulatory proteins cause both benign
and malignant hematologic disorders.
The hematopoietic system is also well suited for an analysis of
the global architecture of the molecular circuits controlling
human cellular differentiation. Hematopoietic stemcells, progen-
itor cells, and terminally differentiated cells can be isolated using
flowcytometry.Moreover,many aspects of hematopoietic differ-
entiation can be recapitulated in vitro. Finally, high-speed
multiparameter flow cytometry and cDNA amplification proce-
dures allow us to purify and profile gene expression from rare
subpopulations (Ebert and Golub, 2004).
Adominantmodelof hematopoiesisposits that it iscontrolledby
a hierarchy of a relatively small number of critical transcription
factors (TFs) that are sequentially expressed, are largely restricted
to a specific lineage, and can interact directly tomediate and rein-
forcecell fatedecisions (Iwasaki andAkashi, 2007).Genetically en-
gineered mice have been used to map the maturation stage at
which key TFs are essential (Orkin and Zon, 2008).
Recent genome-wide studies suggest a more complex archi-
tecture in regulatory circuits involving larger numbers of TFs
that control different combinations of modules of coexpressed
genes (Amit et al., 2009; Suzuki et al., 2009). Complex circuits
with a larger number of TFs than previously assumed, each
with a major regulatory effect, are emerging from studies in
immune cell types (Amit et al., 2009; Suzuki et al., 2009), stem
cell populations (Mu¨ller et al., 2008), and cell differentiation in
invertebrates (Davidson, 2001).
These two views leave open several key questions in under-
standing the regulatory architecture of human hematopoiesis.
(1) Are distinct hematopoietic cell states characterized mostly
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Figure 1. Hematopoietic Differentiation
The 38 hematopoietic cell populations purified by flow sorting and analyzed by gene expression profiling are illustrated in their respective positions in hema-
topoiesis. (Gray) Hematopoietic stem cell (HSC1,2), common myeloid progenitor (CMP), megakaryocyte/erythroid progenitor (MEP). (Orange) Erythroid cells
(ERY1–5). (Red) CFU-MK (MEGA1) and megakaryocyte (MEGA2). (Purple) Granulocyte/monocyte progenitor (GMP), CFU-G (GRAN1), neutrophilic meta-
myelocyte (GRAN2), neutrophil (GRAN3), CFU-M (MONO1), monocytes (MONO2), eosinophil (EOS), and basophil (BASO). (Blue) Myeloid dendritic cell (DENDa2)
and plasmacytoid dendritic cell (DENDa1). (Light green) Early B cell (Pre-BCELL2), pro-B cell (Pre-BCELL3), naive B cell (BCELLa1), mature B cell, class able to
switch (BCELLa2), mature B cell (BCELLa3), and mature B cell, class switched (BCELLa4). (Dark green) Mature NK cell (NK1–4). (Turquoise) Naive CD8+ T cell
(TCELL2), CD8+ effector memory RA (TCELL1), CD8+ effector memory (TCELL3), CD8+ central memory (TCELL4), naive CD4+ T cell (TCELL6), CD4+ effector
memory (TCELL7), and CD4+ central memory (TCELL8). See Table S1 for markers information.by induction of lineage-specific genes or by a unique combina-
tion of modules, wherein the distinct capacities of each cell
type are largely determined through the reuse of modules? (2)
Is hematopoiesis determined solely by a few master regulators,
or does it involve a more complex network with a larger number
of factors? (3) What are the regulatory mechanisms that maintain
cell state in the hematopoietic system, and how do they change
as cells differentiate?
Here, we measured mRNA profiles in 38 prospectively purified
cell populations, from hematopoietic stem cells, throughmultiple
progenitor and intermediate maturation states, to 12 terminally
differentiated cell types (Figure 1). We found distinct, tightly
integrated, regulatory circuits in hematopoietic stem cells anddifferentiated cells, implicated dozens of new regulators in
hematopoiesis, and demonstrated a substantial reuse of gene
modules and their regulatory programs in distinct lineages. We
validated our findings by experimentally determining the binding
sites of four TFs in hematopoietic stem cells, by examining the
expression of a set of 33 TFs in erythroid and myelomonocytic
differentiation in vitro, and by investigating the function of 17 of
these TFs using RNA interference. Our data provide strong
evidence for the role of complex interconnected circuits in hema-
topoiesis and for ‘‘anticipatory binding’’ to the promoters of their
target genes in hematopoietic stem cells. Our data set and
analyses will serve as a comprehensive resource for the study
of gene regulation in hematopoiesis and differentiation.Cell 144, 296–309, January 21, 2011 ª2011 Elsevier Inc. 297
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Figure 2. A Transcriptional Map of Hematopoietic Differentiation
Identifies Lineage-Specific Transcription
(A) Similarity in global expression profiles between proximate differentiation
states. The heat map shows the pairwise Pearson correlation coefficients
between all 211 samples ordered according to the differentiation tree (right
and top). A positive correlation is portrayed in yellow and a negative correlation
in purple.
(B) Signature genes characterizing the five main lineages. Expression levels
are shown for the top 50 marker genes (rows) for each of four major lineages
plus hematopoietic stem and progenitor cells. High relative expression is
298 Cell 144, 296–309, January 21, 2011 ª2011 Elsevier Inc.RESULTS
An Expression Map of Hematopoiesis Reveals Cell
State-Specific Profiles
We defined 38 distinct cell states based on cell surface marker
expression, representing hematopoietic stem and progenitor
cells, terminally differentiated cells, and intermediate states (Fig-
ure 1 and Table S1 available online). For each state, we purified
samples separately from four to seven independent donors by
multiparameter flow cytometry (Experimental Procedures),
yielding 211 samples. Cells from all stem and progenitor popula-
tions were purified from umbilical cord blood. Terminally differ-
entiated lymphocyte populations were purified from peripheral
blood, as terminal differentiation is completed in these cells
upon exposure to antigens after birth (Table S1). In all cases,
cells were harvested fresh and were processed and sorted
immediately. We isolated mRNA from each cell type and
measured expression profiles using Affymetrix microarrays
(Experimental Procedures).
The global transcriptional profiles are consistent with the estab-
lished topology of hematopoietic differentiation. Replicate
samples from a single state but different donors and samples
from multiple states within a lineage are highly correlated with
each other, and profiles from related lineages are also similar
(Figure 2A). Of note, hematopoietic stem cell (HSC) samples do
not form a separate cluster but are highly similar to early progeni-
tors in themegakaryocyte/erythrocytes lineage (MEGA/ERY), sug-
gesting that their transcriptional state is largelymaintained in some
of the early progenitors. These findings are also apparent in
a systematic unsupervised analysis using nonnegative matrix
factorization (NMF) (Brunet et al., 2004) (Figure S1A) and hierar-
chical clustering (Figure S1B). We further validated our data set
by confirming that previously published lineage-specific gene
signatures are significantly enriched in the expected lineage
compared toother lineages (FDR<0.25; FigureS1CandExtended
Experimental Procedures).
Unique and Complex Gene Signatures Characterize
Distinct Hematopoietic Lineages
In a supervised analysis, we found that each of the five dominant
states in our data set—HSPCs, differentiated erythroid cells,
granulocytes/monocytes B cells, and T cells—is distinguished
by a set of significantly differentially expressed genes specific
to each lineage as compared to the others (Figure 2B and
Table S2). Some of these genes are expressed more than
100-fold higher in one cell type (e.g., granzyme genes in certain
T cell and NK cell populations, PROM1 [CD133 antigen], and
HOXA9 in stem and progenitor cells).shown in red and low relative expression in blue; the expression of each gene is
normalized to a mean expression of zero across all the samples; labels as in
Figure 1. Genes were selected by high expression in one lineage compared to
the others (t test).
(C) The number of genes that are differentially expressed, according to an
outlier statistic, was calculated for all hematopoietic cell states profiled (red);
a compendium of 79 tissues in the GNF atlas (Su et al., 2004) (blue); and data
sets of lymphomas (Monti et al., 2005) (turquoise), lung cancers (Bhattacharjee
et al., 2001) (purple), and breast cancers (Chin et al., 2006) (green).
See also Figure S1.
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Figure 3. Expression Pattern and Functional Enrichment of 80 Transcriptional Modules
(A) Average expression levels of 80 gene modules. Shown is the average expression pattern of the genemembers in each of the 80modules (rows) across all 211
samples (columns). Colors and normalization as in Figure 2B. The samples are organized according to the differentiation tree topology (top) with abbreviations as
in Figure 1. The number of genes in each module is shown in the bar graph (left). The expression profiles of a few example modules discussed in the text are
highlighted by vertical yellow lines. The expression of individual genes in each module is shown in Figure S2.
(B) Functional enrichment in genemodules. Functional categories with enriched representation (FDR < 5%) in at least onemodule are portrayed. Categories were
selected for broad representation. The complete list appears in Table S3.
See also Figure S2 and Figure S7.The signature genes are enriched for molecular functions and
biological processes consistent with the functional differences
between lineages (Figure S1D and Table S2). Of note, a set of
16 genes comprised of the 50 partners of known translocations
in leukemias (Mitelman et al., 2010) is enriched in the HSPC pop-
ulation (p < 0.013). This suggests that the 50 partners of leukemia-
causing translocations, containing the promoters of the fusion
genes, tend to be selectively expressed in stem and progenitor
cell populations.
The diversity of gene expression across hematopoietic line-
ages is comparable to the diversity in gene expression observed
across a host of human tissue types. The number of genes that
are differentially expressed throughout our hematopoiesis data
set (outlier analysis) (Tibshirani and Hastie, 2007) (ExtendedExperimental Procedures) is comparable to that determined for
an atlas of 79 different human tissues (Su et al., 2004) and far
higher than in lymphomas (Monti et al., 2005), lung cancers
(Bhattacharjee et al., 2001), or breast cancers (Chin et al.,
2006) (Figure 2C).
Coherent Functional Modules of Coexpressed Genes
Are Reused across Lineages
To dissect the architecture of the gene expression program, we
used the Module Networks (Segal et al., 2003) algorithm (Exper-
imental Procedures) to find modules of strongly coexpressed
genes and associate them with candidate regulatory programs
that (computationally) predict their expression pattern. We iden-
tified 80 gene modules (Figure 3A; modules are numberedCell 144, 296–309, January 21, 2011 ª2011 Elsevier Inc. 299
arbitrarily by the algorithm) covering the 8968 genes that are ex-
pressed in the majority of the samples of at least one cell popu-
lation. The genes in each of the modules are tightly coexpressed
(Figure S2), and the 80 modules have largely distinct expression
patterns (Figure 3A and Figure S2) and are enriched for genes
with distinct biological functions (Figure 3B and Table S3).
A small number of modules are expressed in very specific cell
states and reflect the unique functional capacities of a single
lineage. For example, module 889 is expressed in terminal
erythroid differentiation and is enriched for genes encoding
blood group antigens and organic cation transporters; module
691 is expressed in B lymphocytes and is enriched for genes
encoding immunoglobulins and BCR-signaling pathway compo-
nents; and module 721 is expressed in granulocytes and mono-
cytes and includes genes encoding enzymes and cytokine
receptors that are essential for inflammatory responses.
Conversely, most modules are expressed at varying levels
across multiple lineages, suggesting reuse of their genes in
multiple hematopoietic contexts. These include modules ex-
pressed in both HSC and progenitor populations (e.g., numbers
865, 679, and 805), in both B and T cells (e.g., 673 and 703), in
both granulocyte/monocyte populations and lymphocytes
(e.g., 817, 799, and 649), and across all myeloid (e.g., 583) or
all lymphoid cells (e.g., 931).
Reuse of modules reflects the differential functional require-
ments for specific biochemical programs in the various cell
states. For example, mitochondrial and oxidative phosphoryla-
tion modules (e.g., 847, 583, and 883) are induced in erythroid
progenitors that produce high levels of heme and are affected
most by mitochondrial mutations (Chen et al., 2009; Fontenay
et al., 2006), as well as in granulocytes and monocytes, which
are capable of a respiratory burst following phagocytosis.
Module States Persist through Multiple Differentiation
Steps
To delineate the relation between gene expression and differen-
tiation, we projected each module’s expression pattern onto the
known topology of the differentiation tree (Figure 4 and Fig-
ure S4). For example, consider module 865 (Figure 4A and
Figure S3), which is strongly induced in hematopoietic stem
and progenitor cells and contains genes encoding key HSPC
cell surfacemarkers (CD34 and CD117) and transcriptional regu-
lators (GATA2, HOXA9, HOXA10, MEIS1, and N-MYC). By pro-
jecting the module on the differentiation tree, we observe that
its induced state in HSCs persists through several consecutive
differentiation steps and is repressed at three main points (Fig-
ure 4A, arrowheads): (1) after the granulocyte/monocyte progen-
itor, (2) after erythroid progenitors, and (3) in the differentiation of
HSCs toward the lymphocyte lineage.
We identified a host of such differentiation-associated
patterns in gene regulation. One major pattern (31 modules) is
HSC-persistent states: such modules are active in the HSC state
and persist in an active state in several progenitor populations on
the erythroid/myeloid branch (Figures 4A and 4E), the lymphoid
branch (Figure S4A), or both (Figures S4B and S4H). The HSC
state changes gradually at different points in different modules.
Indeed, only module 631 (Figure S4C) is primarily HSC specific
and includes the known stem cell-specific TFs NANOG and300 Cell 144, 296–309, January 21, 2011 ª2011 Elsevier Inc.SMAD1 (Xu et al., 2008). In other patterns, modules have low
or inactive expression in HSCs but are activated in a single
lineage (10 modules) on either the erythroid/myeloid branch
(Figures 4B and 4C and Figure S4D) or the lymphoid branch (Fig-
ure 4D). In most cases (39 modules), modules are inactive in
HSPCs but are activated in multiple independent lineages (Fig-
ure 4F and Figure S4F).
A Sequence-Based Model of the Regulatory Code
The high degree of coexpression of genes within modules
suggests that they may be coregulated by common transcrip-
tional circuits. We therefore examined each module for enrich-
ment of known and candidate cis-regulatory elements in their
promoters (Extended Experimental Procedures). We used six
motif-finding methods and a motif-clustering pipeline to identify
a nonredundant library of enriched elements. We scored each
module for the enrichment of each of the candidate sites or of
known elements or binding events (Sandelin et al., 2004;
Subramanian et al., 2005) (Extended Experimental Procedures).
We identified 156 sequence motifs and 28 binding profiles of 12
TFs (measured by ChIP) that were enriched in the promoters of at
least one module (data available on http://www.broadinstitute.
org/dmap/). Of these, 66 are previously unannotated motifs,
and 118 are associated with 72 TFs (Table S4).
Of these 72 TFs, 11 are known hematopoietic factors
(Table S4), and their sites are often enriched in modules consis-
tent with their known functions. For example, the site for the
erythroid TF GATA1 (Pevny et al., 1991) is enriched in the late
erythroid module 889, and sites for the lymphocyte regulators
Helios and NFATC (Aramburu et al., 1995; Hahm et al., 1998)
are enriched in the T and NK module 559. We also found signifi-
cant enrichments for TFs with roles in other differentiation
processes, which were not previously implicated in hematopoi-
esis, such as HNF4 a (in the HSPCModule 865) and HNF6 (in the
lymphoid modules 859 and 961).
Tightly Integrated cis-Regulatory Circuits Govern
Differentiation States
To explore how these cis-regulatory associations can give rise to
stable cell states, we assembled the regulatory circuits connect-
ing the 276 TFs whose binding sites were enriched in any gene
set with each other (Figure 5). We connected an edge from
each factor with a known motif to all of the factors that harbor
thismotif in their gene promoters (Extended Experimental Proce-
dures) and focused only on those factors that were expressed in
a given cell state. For example, the circuit of HSC-expressed TFs
with known binding sites (Figure 5A) includes many major known
regulators of the HSC state (Orkin and Zon, 2008), which are
densely interconnected through autoregulatory (12 of 23 active
factors), feedback (15 and 39 loops of size 2 and 3), and feed-
forward (206 loops of size 3) loops. Abnormal expression of
many of the circuit’s TFs is known to cause hematologic malig-
nancies (Look, 1997). This integrated circuitry can give rise to
a robust transcriptional network in terminally differentiated cells
and HSCs. Of note, because the sequence of the binding site for
most TFs is unknown, including 66 of the putative enriched
binding sites, the density of regulation is likely even greater
than we observed.
A HSC and progenitor module (#865)
GATA2, HOXA9, HOXA10, MEIS1, MYCN, DNMT3B, ZNF323, HMGA2
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CEBPA, VDR, SPI1, ATF3, CREB5, PPARGC1A, VENTX, MYCL1 KLF8, E2F5, GABPA, BHLHB3, GCM1
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Figure 4. Propagation and Transitions in Modules’ Expression along Hematopoiesis
Shown are the mean expression levels of the module’s genes in each cell state (colored squares) and selected changes in the predicted regulators, as highlighted
in the text (upward arrowhead, regulator induced; downward arrowhead, regulator repressed). Member genes (rather than regulators) in each module encoding
TFs are noted below each module, as these may reflect alternative regulators at the same differentiation points. TFs that were validated as regulators of erythroid
or granulocyte/monocyte differentiation in a functional assay (Figure 7) are highlighted in bold. The color bar at the bottom of each tree denotes the key lineages,
as in Figure 1.
(A) HSC and progenitor expression in module 865.
(B) Lineage-specific induction in late erythrocytes in module 727.
(C) Lineage-specific induction in granulocytes and monocytes in module 721.
(D) Lineage-specific induction in B cells in module 589.
(E) One-sided propagation of induced state from HSC to the erythroid lineage in module 655.
(F) Reuse of module 817, which is inactive in HSCs and independently induced in both lymphoid cells and granulocytes.
See also Figure S3 and Figure S4.During the course of differentiation, the HSC circuit gradually
disappears along multiple lineages due to loss of expression of
the relevant TFs (Figure 5A and data available on http://www.broadinstitute.org/dmap/). Conversely, in terminally differenti-
ated cells, other dense circuits emerge through the induction
of other TFs. For example, the 14 factors in the erythroid circuitCell 144, 296–309, January 21, 2011 ª2011 Elsevier Inc. 301
AB
HSC network
Late erythrocyte network
HSC MEP Early ERY Late ERY
TF
Active in phase
Correlated
Uncorrelated
Inactive
Figure 5. Dynamic Organization of Tightly Integrated cis-Regulatory Circuits in HSCs and Erythroid Cells
(A and B) Shown are cis-regulatory networks between TFs (nodes) that are enriched in at least one gene set and are expressed (fold change > 1.5) in (A) HSCs or
(B) late erythroid cells. Nodes represent TFs that are expressed (purple) or not (gray) in each of the four phases of the erythroid lineage (HSC, MEP, early ERY, and
late ERY). An edge from node a to node b indicates that the promoter of the gene in node b has a binding site for the TF encoded by the gene in node a. Edge colors
indicate the Pearson correlation between the expression profiles of the TFs in the connected nodes: red, positive correlation (coefficient > 0.4); black, no
correlation (absolute Pearson% 0.4); gray, nonactive edge (at least one of the two connected nodes was not expressed in that phase). See Table S4 for enriched
motif information.includemany of the knownmajor regulators of erythroid differen-
tiation (Cantor and Orkin, 2002), including GATA1, LMO2,
FOXO4, NFE2, and RXRA (Figure 5B). We find similarly distinct
networks in the granulocyte lineage, T cells, and B cells.
Hundreds of Transcription Factors Are Differentially
Expressed across Lineages in Coherent Modules
The dense regulatory circuits between TFs in our sequence-
based model suggest that the expression of TF genes is likely
to be highly regulated in hematopoiesis. Indeed, supervised
analysis finds that many TF genes are strongly differentially ex-
pressed in each primary lineage (Figure 6A and Figure S5A)
and that the diversity of TF gene expression is comparable
between hematopoiesis and the tissue compendium (Su et al.,
2004) (Figure S5B).
Some TFs are expressed predominantly in a single lineage,
includingwell-studiedTFs that are known to beessential for differ-
entiation in HSCs or a particular lineage (Figure S6). However, the
expression of those factors often increases gradually along differ-
entiation (Figures S6D, S6H, and S6I), similar to the gradations
observed in gene modules (Figure 4 and Figure S4).
Many other TFs are ‘‘reused’’ across lineages either through
persistent expression from a single progenitor population or by
independent activation in multiple lineages (Figure 4 and
Figure S4). For example, module 793 (Figure S4F), which is302 Cell 144, 296–309, January 21, 2011 ª2011 Elsevier Inc.induced in both B cells and late erythroid cells, includes several
TFs and chromatin regulators. Among these, KLF3 has a re-
ported role in erythroid cells (Funnell et al., 2007), whereas
NFAT5 has a demonstrated function in B cells (Kino et al., 2009).
Many TFs—not previously associated with these lineages—are
expressed similarly to known factors and belong to the same
modules, suggesting that the transcriptional circuit consists of
a greater number of TFs than previously assumed. For example,
the late erythroid module 727 (Figure 4B) contains four TFs: two
are known erythroid TFs (GATA1 and FOXO3A) (Bakker et al.,
2007), whereas the others (NFIX1, MYT1) were not previously
linked to erythropoiesis. Similarly, the granulocytes/monocytes
module 721 (Figure 4C) contains eight TFs, only two with known
roles in the lineage (CEBPA and PU.1/SPI1).
An Expression-Based Model of the Regulatory Code
of Hematopoiesis Identifies Putative Regulators
Controlling Changes in Differentiation
To identify the potential regulatory role of differentially expressed
TFs, we examined the combinations of TFs (regulatory program),
which theModule Networks algorithm (Segal et al., 2003) used in
order to ‘‘explain’’ the expression of each of the 80 modules
(Experimental Procedures). For example, the algorithm associ-
ated module 865 (Figure S3, bottom) with five regulators, most
prominently PBX1 (‘‘top regulator’’) and SOX4 (‘‘2nd level
Figure 6. Lineage-Specific Regulation of TF Expression
Signature TF genes with lineage-specific expression in the five main lineages. Shown are the expression levels of the top 50 marker TF genes (rows) selected for
each of four major lineages plus hematopoietic stem and progenitor cells (labels as in Figure 1). Genes were selected by high expression in one lineage compared
to the others (t test). High expression is shown in red and low expression in blue; the expression of each gene is normalized to amean expression of zero across all
the samples. See also Figure S5 and Figure S6.regulator’’) (Figure S3, top). It predicts that, when both PBX1 and
SOX4 are induced (in HSCs, CMPs, MEPs, GMPs, early ERY,
and early MEGA cells), the module’s genes are induced too.
PBX1 is an established regulator of HSPCs, and SOX4 has
recently been shown to be a direct target of HOXB4, a known
HSC regulator (Lee et al., 2010), supporting the algorithm’s
result. The regulators were chosen by their expression alone,
and though the model chooses one combination of ‘‘representa-
tive’’ regulators, there may be several highly similar TFs that
could fulfill the role.
We next interpreted these regulatory connections within the
context of the lineage tree. We associated each regulator with
the tree positions (Figure 4 and Figure S4, arrowheads), in which
a change in the regulator’s expression is associated with
a change in the module’s expression. For example, there are
four such positions for PBX1 and SOX4 inmodule 865 (Figure 4A,
arrowheads), such as the association between the repression
of PBX1 and the repression of the module in differentiation
toward lymphoid lineages (Figure 4A, downward arrows, labeled
PBX1). In this way, we predict the roles of distinct TFs at distinctdifferentiation points, such as MNDA at the granulocyte/mono-
cytes progenitor (Figure 4C and Figure S4G) or NCOA4 and
KLF1 at late erythrocytes (Figure S4D).
Overall, the algorithm associated 220 TFs (Table S3) with at
least one regulatory program and 63 TFs as top regulators (e.g.,
FigureS3, top) of at least onemodule. These include15TFsprevi-
ously associatedwith hematopoiesis (e.g., TAL1, KLF1, BCL11b,
LMO2, and MYB) and 7 associated with differentiation in other
systems (e.g., CREG1, MEF2A, and NHLH2). For example, we
correctly found HOXA9 associated with HSPCs and early
erythroid induction (module 679); NFE2, RXRA, KLF1, and
FOXO3 associated with late erythroid induction (modules 727,
895, 889, and 739) (Figure 4B and Figure S5D); HIVEP2 and
BCL11b associated with T cell induction (modules 859, 949,
and 667); and HOXC4 and POU2AF1 associated with B cell
induction (module 589) (Figure 4D). In addition, the algorithm pre-
dicted a regulatory role for proteins thatwere not previously asso-
ciated with regulating hematopoietic differentiation (e.g., MNDA
and NCOA4). The selected regulators are enriched for TFs that
are known to participate as 30 partners in fusions in hematologicCell 144, 296–309, January 21, 2011 ª2011 Elsevier Inc. 303
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Figure 7. Experimental Validation of 33 TFs
(A) The expression of 33 TFs was detected in primary human bone marrow CD34+ progenitor cells undergoing differentiation in vitro, harvested at 12 time points
between days 3 to 10 of differentiation, and detected by amultiplexed assay using LMA followed by fluorescent bead-based detection (left heat map). In the heat
map in the right panel, the expression of the same TFs in the original Affymetrix data set is illustrated. The labels at the far left indicate whether the TF was chosen
as a regulator in the expression-based model or in the sequence-based model.
(B) Differentiation following TF silencing with shRNA. Human bone marrow CD34+ cells expressing shRNAs targeting TFs were induced to differentiate in vitro for
10 days, and the ratio of erythroid (glycophorin A-positive) and myelomonocytic (CD11b-positive) cells was measured by flow cytometry. Each black dot
represents an individual shRNA (mean of three replicates), and bars indicate their average. The effect of a control shRNA targeting the luciferase gene, which is not
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cancers (Mitelman et al., 2010) (25 of the regulators; p < 0.028),
consistent with a regulatory role in hematopoiesis.
Finally, we compared the predictions of the expression- and
sequence-based models. The two models were different due
to two reasons. First, 85% of the TFs chosen as regulators in
the expression model (187 of 220) do not have a characterized
binding motif in current databases and cannot be identified in
the sequence model. Second, 29 of 41 TFs (70%) whose known
sites are incorporated in the sequence model and appear in the
expression model show little or no correlation in expression
(absolute Pearson < 0.4) to the module with which they are asso-
ciated in the sequence model (data available on http://www.
broadinstitute.org/dmap/). Thus, the two models are likely
complementary, each capturing a substantial but distinct
number of known regulators in the relevant states. To gain confi-
dence in their predictions, we next pursued experimental
approaches.Direct Targets of MEIS1, TAL1, IKAROS, and PU.1 in
HSPCs Reveal Dense Circuits and Anticipatory Binding
To validate and further investigate the gene modules and cis-
circuits, we examined the direct binding of TFs across the
genome using chromatin immunoprecipitation followed by
sequencing (ChIP-Seq) in HSPCs. We analyzed the binding of
MEIS1, TAL1, PU.1/SPI1, and IKAROS/IKZF1, four key regula-
tors of the specification, maintenance, or differentiation of
HSCs (Argiropoulos et al., 2007; Le´cuyer and Hoang, 2004; Ng
et al., 2007; Singh et al., 1999), in two replicates, often in inde-
pendently expanded populations of primary human HSPCs
(Extended Experimental Procedures). We scored each experi-
ment for statistically significant binding (Extended Experimental
Procedures and Table S5) and tested each of our expression
modules for enrichment in binding events (Table S5).
In modules whose genes are highly induced in terminal differ-
entiation, we found enrichment of binding by corresponding
lineage specific factors in HSPCs, suggesting anticipatory regu-
lation. For example, module 727 (Figure 4B), expressed in termi-
nally differentiated erythroid cells, was enriched with target
genes bound in HSPCs by TAL1, an erythroid transcription factor
(Table S5). Similarly, genes in the granulocyte/monocyte module
763 were enriched for targets bound by PU.1 in HSPCs (Table
S5), and genes in the lymphoid module 949 were enriched for
target genes bound by IKAROS in HSPCs (Table S5). In many
(but not all) cases, expression of the target module is already
moderate in HSCs and increases with differentiation. This
strongly supports an anticipatory regulation in which relevant
differentiation TFs are bound at target promoters in HSPCs, re-
sulting in mild expression of targets that persists and further
increases upon differentiation.
Some of our expression-basedmodel’s predictions for HSPCs
are supported by the ChIP-Seq data. For example, the twoexpressed in human cells, is indicated with a dashed line. Below the shRNA lab
Classification of the TFs according to their roles in the expression-based and se
(C) The effects of additional shRNAs targeting candidate TFs expressed in CD3
assayed as in (B) (*p < 0.01).
(D) Representative flow cytometry scatter plots from shRNAs expressed in umbi
See additional information in Table S5, Table S6, and Table S7.modules that are induced in HSPCs and are associated in our
model with either MEIS1 (module 961) or its known binding
partner PBX1 (module 865, Figure 4A) are enriched in target
genes bound by MEIS1. MEIS1 and HOXA9 are members of
module 865, consistent with MEIS1’s autoregulatory binding
(Table S5). The ChIP-Seq data also support module reuse. For
example, several of the modules enriched with PU.1 are reused
in granulocytes and B lymphoid cells (e.g., modules 853, 649,
979, 769, and 817), consistent with an established role for
PU.1 in both lineages. In other cases, module reuse may be
mediated by combinatorial binding of two factors (e.g., by both
PU.1 and IKAROS in module 607, which is expressed in granulo-
cytes, monocytes, and some lymphoid cells).
The individual binding events in our profiles also support the
overall organization observed in the cis-circuits in the sequence
model. First, three of the factors bind their own promoter
(IKAROS and MEIS1) or enhancer (PU.1), forming autoregula-
tory loops, as observed for many known master regulators
(Boyer et al., 2005) and in our sequence model. Second,
PU.1, IKAROS, and MEIS1 are integrated in a feed-forward
loop. Third, there is a significant overlap between the targets
of any pair of factors (Table S5). Finally, in aggregate, the
factors bind 13 of the 23 other TFs in our HSC circuit, further
increasing its density.Differential Expression of Candidate Transcription
Factors during In Vitro Differentiation
We confirmed the lineage-specific expression of 33 TFs in
primary human hematopoietic progenitor cells induced to
differentiate in vitro. We focused on the erythroid andmyelomo-
nocytic lineages, as differentiation of primary human hemato-
poietic progenitor cells can be faithfully recapitulated and
genetically manipulated along these lineages in vitro. We
selected a set of 33 TFs identified in either the sequence or
gene expression-based models as candidate regulators of
these two lineages.
We developed a quantitative, multiplexed assay to detect the
expression of the signature genes in a single well using ligation-
mediated amplification (LMA) followed by amplicon detection on
fluorescent beads (Peck et al., 2006). We cultured primary
human CD34+ cells from adult bone marrow in vitro in cytokine
conditions promoting either erythroid or myelomonocytic differ-
entiation. We harvested cells at 12 time points between days 3
and 10 of erythroid and myelomonocytic differentiation and
determined TF gene expression using the multiplexed bead-
based assay. We confirmed that the 33 TFs are differentially
expressed between the two lineages, providing a robust expres-
sion signature that can distinguish between the two states inde-
pendent of profiling platform in cells derived from adult bone
marrow or umbilical cord blood and in cells that differentiated
in vivo or in vitro (Figure 7A).els, * or ** indicates p < 0.05 for one or both shRNAs, respectively. (Bottom)
quence-based models and to their induction pattern in the LMA profiling.
4+ cells derived from both umbilical cord blood and adult bone marrow and
lical cord blood.
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Changes in Expression Levels in Transcription Factor
Circuits Functionally Modulate Differentiation In Vitro
We next tested whether acute loss of expression of each TF
using RNA interference can functionally affect erythroid and
myelomonocytic differentiation. We used our multiplexed
bead-based assay to identify short hairpin RNAs (shRNAs) that
effectively knock down each TF and found 17 genes with at least
two different effective shRNAs. Next, we infected primary human
adult bone marrow CD34+ cells with the validated lentiviral
shRNAs, cultured the cells in cytokine conditions supporting
both erythroid and myelomonocytic differentiation, and as-
sessed the number of erythroid (glycophorin A-positive) cells
relative to myelomonocytic (CD11b-positive) cells by flow
cytometry (Figure 7B). In most cases, the shRNA perturbation
dramatically altered differentiation, with the ratio of erythroid to
myeloid cells ranging from less than 1:10 to more than 10:1
with different shRNAs.
The perturbations associated with the lowest fraction of
erythroid cells in culture corresponded to the samples express-
ing shRNAs targeting nine TFs expressed at higher levels in the
erythroid lineage (Table S6). Consistent with our models, six
were regulators in either the expression or the sequence model,
and the other three were members of erythrocyte-induced
modules (Figure 7B, bottom). These include GATA-1 and KLF1,
TFs with well-established roles in erythroid differentiation
(Funnell et al., 2007; Pevny et al., 1991), and TAL1 and FOXO3A,
which have been implicated in erythroid differentiation (Aplan
et al., 1992; Bakker et al., 2007). The TF YY1 was identified in
our sequence-based models, has higher expression in erythroid
cells, and was functionally validated by our shRNA screen.
A physical association between YY1 and GATA-1 was reported
in the chicken a-globin enhancer (Rinco´n-Arano et al., 2005).
Finally, we validated a new role for HIF3A and AFF1 (AF4) in
erythroid differentiation based on module membership and
perturbation. Of note, AFF1 is a common translocation partner
with the MLL gene in leukemia (Li et al., 1998).
Conversely, eight perturbations resulted in the lowest fraction of
myelomonocytic cells and corresponded to samples expressing
shRNAs targeting seven TFs induced in granulocyte/monocyte
cells and one (E2F1) with higher expression in erythroid cells.
Four TFs were predicted by the expression model to regulate
modules induced in granulocytes/monocytes, and five were pre-
dicted in the sequencenetwork (Figure 7B, bottom). These include
the well-established granulocyte/monocyte TFs, PU.1/SPI1 and
C/EBP family members (Hirai et al., 2006; Scott et al., 1994), and
VDR, a gene that has been implicated in myeloid differentiation
(Liu et al., 1996).
We further validated three TFs that had not previously been
associated with erythroid differentiation (AFF1, HIF3A, and YY1)
alongside a known erythroid regulator (FOXO3A) and a known
granulocyte regulator (PU.1/SPI1) (Figures 7Cand7D).We tested
additional shRNAs for each gene by quantitative PCR and identi-
fied two shRNAs per gene that decrease expression of their
target genes by 63% to 95% in human CD34+ cells derived
from both adult bone marrow and umbilical cord blood. Using
flow cytometry for lineage-specific markers following 10 days
of differentiation, we validated our initial findings that AFF1,
HIF3A, and YY1 decrease the relative production of erythroid306 Cell 144, 296–309, January 21, 2011 ª2011 Elsevier Inc.lineage cells. These results are further supported by profiling
mRNA levels following knockdown of these five TFs at 4 days
following lentiviral infection. Compared to a control shRNA,
gene expression in cells expressing AFF1, HIF3A, and FOXO3A
were anticorrelated with erythroid profiles and positively
correlated with granulocytes (Figure S5C), and knockdown of
PU.1/SPI1 had the inverse pattern, as expected. Knockdown of
YY1 caused a transcriptional profile more similar to HSCs, indi-
cating a more substantial block in terminal differentiation. Taken
together, our findings indicate that modulating the expression of
TF genes can powerfully alter hematopoietic differentiation.
Web-Based Portal as a Research Resource
To facilitate interrogation of our hematopoietic gene expression
database by the broader scientific community, we have created
a Web-based portal (http://www.broadinstitute.org/dmap) to
provide access to the primary data, sample information, pro-
cessed results from both models, and a suite of analytic tools.
DISCUSSION
General Principles of Transcriptional Circuits
in Differentiation
The changes in gene expression over the course of hematopoi-
etic differentiation are profound. The number of differentially ex-
pressed genes is similar within hematopoiesis and across human
tissues, suggesting comparable complexity. Our findings reveal
several major principles about the organization of this transcrip-
tional program.
Gene expression in hematopoiesis can be decomposed into
modules of tightly coexpressed genes, some of which are
restricted to specific lineages, whereas most are reused in
multiple lineages. Furthermore, a module’s transcriptional state
persists through multiple differentiation steps. For example, the
transcriptional state of HSCs is not switched off immediately
but instead persists with gradually decreasing expression in
progenitor cells.
Many of the TFs with known binding sites can be assembled
into densely interconnected circuits. These can provide a mech-
anism for robust gene regulation in both terminally differentiated
cells and HSCs. Because the binding sites for many factors
remain unknown, we therefore expect that the circuit’s density
and complexity is even higher.
A large number of TFs are differentially expressed across
hematopoiesis, often in tightly coregulated modules, and at
comparable complexity to that of the other (nonregulatory)
genes. Leveraging this correspondence, we associated TFs to
the modules and differentiation states that they may regulate.
We automatically rediscovered (without prior knowledge) many
of the key known TFs and predict regulatory functions for
numerous additional TFs.
By monitoring the binding of four major TFs in HSPCs, we
found that anticipatory regulation may be a major feature of
these circuits. In such cases, TFs that direct lineage-specific
differentiation bind a significant portion of their target genes in
HSPCs. These target genes are often moderately expressed in
the stem and progenitor cells, with substantial further induction
as differentiation progresses in the relevant lineage. This is
consistent with the concept of ‘‘lineage priming’’ in HSCs (Aka-
shi, 2005), providing flexibility in cell fate commitments.
Discovering and Validating Transcriptional Regulators
in Hematopoiesis
Our examination of the global architecture of hematopoietic differ-
entiation offers a complementary strategy to studies of individual
genes in murine models. In this approach, gene expression and
sequence-based analyses nominate a host of candidate regula-
torsandpoint togroupsof factors thatmayact togetherandhence
introduce redundancies. The two computational approaches
complement each other: the expression model may identify
factorswhosebinding specificity is unknown, the sequencemodel
may help detect those factors whose mRNA levels do not change
or do not correspond to changes in targets (Lu et al., 2009).
We used a perturbation-based approach to validate TFs
derived from the sequence and expression models in an in vitro
differentiation system. Modulating expression of candidate TFs
with RNA interference altered differentiation of hematopoietic
progenitor cells in vitro in the direction predicted by our models.
We reconfirmed the role of several known factors and identified
several new ones (e.g., YY1, AFF1, and HIF3A). In vitro manipula-
tion can be more sensitive than genetic ablation experiments
in vivo, wherein perturbations may be corrected by homeostatic
mechanisms, such as cytokine or transcriptional feedback loops.
A Transcriptional Roadmap for Hematologic
Malignancies
Balanced translocations involving TFs play a major role in the
pathogenesis of human leukemias. Of 200 known translocations
in AML (Mitelman et al., 2010), there are 53 in which at least one
translocation partner is a TF, 16 as a 50 partner, and 43 as a 30
partner (6 in both). Twenty-five of these 43 known 30 partners
are among the 220 regulators in the expression model (p <
0.028), and 5 of the known 30 partners are among the 72 known
TFs in the sequence model. Furthermore, 50 partners are en-
riched in genes expressed in HSPCs. These results support
the role of chosen regulators in differentiation and are consistent
with a broader paradigm in which lineage-specific promoters
can dysregulate key TFs to disrupt differentiation (Rosenbauer
and Tenen, 2007; Tomlins et al., 2005).
Impaired or blocked hematopoietic differentiation is a defining
characteristic of leukemia, and the gene expression profiles of
leukemias cluster strongly into subgroups that correspond to
specific molecular subgroups (Bullinger et al., 2004; Tamayo
et al., 2007; Valk et al., 2004). Gene signatures induced in various
leukemias significantly overlap those induced in normal hemato-
poiesis (Figures S7A and S7B). In most cases, there is a coherent
overlap between the leukemia subtype and the cell type from
which it is known to arise. However, human leukemias often
express more complex combinations of modules that are not
observed in normal samples, including HSPC modules, as has
been reported inmurinemodels of leukemia (Krivtsov et al., 2006).
Toward a Programming ‘‘Code’’ of Hematopoietic
Differentiation
A more complete understanding of hematopoietic differentiation
will likely require an integration of gene expression data withother genomic data, including epigenetic analyses, genome-
wide ChIP-Seq studies, proteomics, and systematic functional
studies. Given the ability to produce high-quality measurements
from small numbers of cells, gene expression data provides
a first draft of the transcriptional program controlling hematopoi-
esis, opening the way to manipulate and reprogram these
circuits, through perturbation and manipulation of each regula-
tory factor. These can highlight avenues for therapeutic interven-
tion, including ‘‘reprogramming’’ of cells to more desired states.
Though deriving mechanistic models from mammalian gene
expression profiling data has been challenging, hematopoiesis
provides a paradigm for the testing of more advanced algorithms
(Kim et al., 2009). Our data set and analyses provide a resource
for further inquiries into normal and pathologic hematopoietic
differentiation in humans.EXPERIMENTAL PROCEDURES
Further details for data analysis, chromatin immunoprecipitation, and func-
tional validation experiments are described in the Extended Experimental
Procedures.Subjects and Samples
Human umbilical cord blood was harvested from postpartum placentas at
Brigham and Women’s Hospital under an Institution Review Board (IRB)-
approved protocol. Peripheral blood samples were obtained from healthy
volunteers at the Dana-Farber Cancer Institute with informed consent under
an IRB-approved protocol.
The majority of cells were purified from umbilical cord blood, an enriched
source of undifferentiated populations. However, terminally differentiated
lymphocyte populations, including T cells (TCELL1-8), B cells (BCELL1-4),
natural killer cells (NKa1, NKa2, NKa3, and NKT), and dendritic cells (DENDa1
and DENDa2), were purified from adult peripheral blood because terminal
differentiation in these populations requires exposure to antigens after birth.
For each cell population, we purified samples from four to seven distinct
donors. All blood samples were harvested fresh and immediately processed
for flow sorting.Cell Sorting Strategy and Flow Cytometry
First, mononuclear cells were isolated by Ficoll-Hypaque sedimentation. For
relatively rare populations, including hematopoietic stem cell populations
(HSC1andHSC2), progenitor populations such ascommonmyeloid progenitor
(CMP), megakaryocyte/erythroid progenitor (MEP), granulocyte-monocyte
progenitor (GMP), and the erythroid lineage populations (ERY1–5), lineage
depletion was performed using antibodies against CD2, CD3, CD4, CD5,
CD8, CD11b, CD14C, CD19, and CD56 with a magnetic column (Miltenyi Bio-
tec, Auburn, CA). Positive selection was then performed using flow cytometry
for labeled antibodies to the markers described in Table S1. For the more
common or terminally differentiated populations, including neutrophil popula-
tions (GRAN1-3), basophils (BASO1), monocytes (MONO1–2), eosinophils
(EOS2), megakaryocytes (MEGA1–2), B-lymphoid progenitor (PRE_BCELL1),
pro and early B lymphocytes (PRE_BCELL2 and PRE_BCELL3), dendritic cells
(DENDa1andDENDa2),mature Tcells (TCELL1–8),matureBcells (BCELL1–4),
and natural killer cells (NKa1–3, NKT), cells were positively selected using flow
scatter properties and antibodies based on the immunophenotypes described
in Table S7. The gene expression profiles for a subset of the lymphoid popula-
tions has been analyzed previously (Haining et al., 2008).
Sorting was performed with Vantage SE. Diva or FACSAria flow cytometers
(Becton Dickinson, San Jose, CA). Cell populations of interest were collected
into tubes containing PBS in a collection unit at 4C. The > 95% purity of pop-
ulations was confirmed by performing FACS analysis of the sorted cells.
Sorted cells were spun down, immediately resuspended in TriZol (Invitrogen,
San Diego, CA), and stored at 70C.Cell 144, 296–309, January 21, 2011 ª2011 Elsevier Inc. 307
Microarray Data Acquisition
Total RNA was isolated from TriZol. The concentration of RNA was quantified
using the RiboGreen RNA Quantitation Kit (Invitrogen, San Diego, CA). Ten
nanograms of total RNA were amplified using the Ovation Biotin RNA Amplifi-
cation and Labeling System (NuGEN, San Carlos, CA). The cDNA was frag-
mented, labeled, and hybridized to Affymetrix HG_U133AAofAv2 microarrays
(Affymetrix, Santa Clara, CA), which contain 22,944 probes.
Expression-Based Module Networks Model
The modules and their regulation programs were automatically learned using
the Module Networks algorithm (Segal et al., 2003). This method detects
modules of coexpressed genes and their shared regulation programs. The
regulation program is a small set of genes whose expression is predictive of
the expression level of the module genes using a decision (regression) tree
structure. Given the expression values and a pool of candidate regulator
genes, a set of modules and their associated regulation programs are auto-
matically inferred by an iterative procedure. This procedure searches for the
best gene partition into modules and for the regulation program of each
module while optimizing a target function. The target function is the Bayesian
score derived from the posterior probability of themodel (see Segal et al., 2005
for a detailed description of the algorithm).
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Data set is available on http://www.ncbi.nlm.nih.gov/geo/, GSE24759.
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